This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): gallium nitrate
Description: Although the exact mechanism of action is unknown, Ganite is believed to exert a hypocalcemic effect by inhibiting calcium resorption from bone:
- Gallium nitrate localizes preferentially where bone resorption and remodeling is occurring
- Gallium nitrate inhibits osteoclast activity
- Inhibition of resorption may occur via a reduction in increased bone turnover.
Deal Structure: Ganite was developed as a drug in the U.S. by Fujisawa, the National Cancer Institute, and the Memorial Sloan-Kettering Cancer Center. Sloan-Kettering licensed its Ganite rights to private company Relgen in 1999, and Relgen in turn licensed its rights to Genta in 2000.
In March 2007, Genta and IDIS announced the signing of an agreement whereby IDIS will distribute Ganite and Genasense Injection, on a named patient/compassionate use basis. The global agreement covers all territories except the United States. Genta expects to allocate a percentage of net proceeds from the IDIS program to support compassionate use in indigent patients; the remainder will support further clinical research.
Idis and Clinigen
In April 2015, Clinigen announced that it has agreed to acquire the entire issued and to be issued share capital of Idis for an enterprise value of 225.0 million (calculated on a cash-free debt-free basis). Clinigen is financing the Acquisition and associated...See full deal structure in Biomedtracker
Partners: Clinigen Group plc
Pink Sheet Genta Stops Active Marketing Of Ganite
Additional information available to subscribers only: